Theratechnologies (THTX)
(Delayed Data from NSDQ)
$1.72 USD
+0.06 (3.61%)
Updated Jan 14, 2025 04:00 PM ET
After-Market: $1.69 -0.03 (-1.74%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
THTX 1.72 +0.06(3.61%)
Will THTX be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for THTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for THTX
Why Fast-paced Mover Theratechnologies (THTX) Is a Great Choice for Value Investors
Despite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain Stock
THTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum
Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?
Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock
Other News for THTX
Theratechnologies issues update on Egrifta SV shortage
Theratechnologies Seeks FDA Approval for Manufacturing Changes to EGRIFTA SV®
Theratechnologies announces filing of PAS with FDA for manufacturing environment
Theratechnologies announces filing of PAS with FDA for manufacturing environment
Theratechnologies Seeks FDA Approval for EGRIFTA SV® Changes